Cargando…
Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia
INTRODUCTION: This phase 2 trial evaluated the safety, tolerability, and feasibility of repeated infusions of the plasma fraction GRF6019 in mild‐to‐moderate Alzheimer's disease. METHODS: In this randomized, double‐blind, dose‐comparison trial, 47 patients were randomized 1:1 to receive daily i...
Autores principales: | Hannestad, Jonas, Koborsi, Katie, Klutzaritz, Vicki, Chao, Whitney, Ray, Rebecca, Páez, Antonio, Jackson, Sam, Lohr, Scott, Cummings, Jeffrey L., Kay, Gary, Nikolich, Karoly, Braithwaite, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744029/ https://www.ncbi.nlm.nih.gov/pubmed/33344754 http://dx.doi.org/10.1002/trc2.12115 |
Ejemplares similares
-
Deep Longitudinal Proteomics Profiling Reveals Biological Pathways Responding to GRF6019 in Two AD Clinical Trials
por: Lehallier, Benoit, et al.
Publicado: (2021) -
RasGrf1 and Aging
por: Davies, Kelvin J. A., et al.
Publicado: (2011) -
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia
por: Bido, Simone, et al.
Publicado: (2015) -
Genome-Wide Identification and Evolution of the GRF Gene Family and Functional Characterization of PbGRF18 in Pear
por: Zhu, Rongxiang, et al.
Publicado: (2023) -
Genome-wide identification of GRF transcription factors in soybean and expression analysis of GmGRF family under shade stress
por: Chen, Feng, et al.
Publicado: (2019)